Financials
Financial year 2025
PHARMACIE STIBBE from Ganshoren, company number BE0829133630, closed financial year 2025 with a result of € 53,085 after tax. For that financial year PHARMACIE STIBBE recorded a gross margin of € 292,317 and equity of € 197,594. Compared with financial year 2024, the result moved from € 97,809 to € 53,085. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 11, 2026.
€ 197,594
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 53,085
▼ 46% vs 2024
Profit after tax over the fiscal year.
€ 46,810
▼ 33% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 39,184 paid out
74 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
3.3
Average over the fiscal year, from the social balance sheet.
€ 201,011
▲ 7% vs 2024
€ 60,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,081
▼ 40% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 23,155
▼ 29% vs 2024
€ 9,445 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 52,501
Supplier invoices still open on the last day of the fiscal year.
€ 31,018
▼ 40% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 309,182 | € 279,476 | € 341,757 | € 292,317 | ▼ 14% |
| Profit after taxes | € 35,279 | € 43,035 | € 97,809 | € 53,085 | ▼ 46% |
| Equity | € 121,217 | € 125,068 | € 183,693 | € 197,594 | ▲ 8% |
| Total debts | € 216,768 | € 239,638 | € 216,039 | € 162,934 | ▼ 25% |
| Cash | € 69,458 | € 75,899 | € 69,408 | € 46,810 | ▼ 33% |
| Retained profit | € 79,217 | € 83,068 | € 141,693 | € 155,594 | ▲ 10% |
| Dividend | € 34,384 | € 39,184 | € 39,184 | € 39,184 | |
| Bank debt | € 53,208 | € 41,482 | € 32,411 | € 23,155 | ▼ 29% |
| Balance sheet total | € 337,985 | € 364,706 | € 399,732 | € 360,528 | ▼ 10% |
| Employees (FTE) | 3.6 | 3.4 | 3.3 | 3.3 |
Key figures of PHARMACIE STIBBE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE STIBBE?
What happened at PHARMACIE STIBBE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 53,085 (▼ 46% vs 2024). filed late Source: NBB ↗
- New establishment in Ganshoren. KBO
- Start of the company according to the CBE. KBO
In short
From € 35,279 profit in 2022 to € 53,085 profit in 2025.
Paid € 83,246 in corporate taxes since 2022.
Best year ever: 2024, with € 97,809 profit.
On average € 88,600 of value added per employee in 2025.
A new publication or filing at PHARMACIE STIBBE? We notify you, reason included.
Follow PHARMACIE STIBBEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of STIBBEPHAR comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIE STIBBEBehind PHARMACIE STIBBE is MARC STIBBE. The shares are held by STIBBEPHAR (49%).
Directors
According to the 2025 annual accounts
Shareholders
49%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Keizer Karellaan 73 box a
1083 Ganshoren
Keizer Karellaan 73A
1083 Ganshoren
Active since 9 September 2010
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0829.133.630
- VAT number
- BE 0829.133.630
- Registered office
- Keizer Karellaan 73 bus a, 1083 Ganshoren
- Names & denominations
- PHARMACIE STIBBE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 September 2010
- Peppol
- Active · Active since 12 Nov 2025
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten
Overige detailhandel in voedingsmiddelen, neg
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.